week 1 results

with Wynzora1,*

And continual clearance of plaque psoriasis flare-ups through week 82,†,‡

Ease of use influences patient adherence3

Up to 75% of patients are nonadherent to topical treatments, with the most frequent reasons for discontinuation including their time-consuming nature and poor cosmetic characteristics.3

"Cosmetic acceptability and ease of use affect treatment preference and adherence, with patients generally preferring less messy treatments that are easy to apply.3"

- Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis.
J Eur Acad Dermatol Venereol. 2011;25(suppl 4):9-14

Convenience that patients can celebrate4

Patient-perceived treatment convenience was assessed in clinical trials on a numerical scale in the following categories4:

Ease of application impacts perceived treatment convenience Greasiness of application impacts perceived treatment convenience Moisturization of skin impacts perceived treatment convenience Disruption of daily routine impacts perceived treatment convenience Greasy residue impacts perceived treatment convenience
Wynzora achieved a patient treatment convenience score of 42 out of 50 (n=343)

*Wynzora cream (36.0%) demonstrated ≥1-grade PGA improvement in significantly more patients than vehicle (12.6%) at week 1 (P<0.0001).5
Wynzora cream (37.4%) was noninferior to calcipotriene/betamethasone dipropionate topical suspension, 0.005%/0.064% (22.8%) for the primary endpoint of treatment success at week 8.1
When used as directed.
§At participating pharmacies. Limitations apply. Reduced copay for commercially insured eligible patients. Uninsured and government-insured patients are not eligible for these offers. See rebate card for details.

PGA: Physician Global Assessment.


Important safety information

INDICATION: Wynzora® (calcipotriene and betamethasone dipropionate) Cream, 0.005%/0.064% is indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older. ADVERSE EVENTS: In the pivotal trial, the most common adverse reactions (≥1%) were: upper respiratory infection (7%), headache (2%), and application site infection (1%). WARNINGS AND PRECAUTIONS: For topical use only. Patients should not use more than 100g of Wynzora® Cream per week. Do not use near or in the mouth, eyes or intravaginally. Avoid using Wynzora® Cream on the face, groin or armpits, or if they have atrophy at the treatment site. Discontinue use once plaque psoriasis is under control or at 8 weeks. Do not use Wynzora® Cream with occlusive dressings. Hypercalcemia and hypercalciuria have been observed with topical use of calcipotriene. Wynzora® Cream can cause reversible HPA axis suppression with the potential for clinical glucocorticosteroid insufficiency during and after withdrawal of treatment. Wynzora® Cream may cause vision problems, including increasing the risk of cataracts and glaucoma. It is not known if Wynzora® Cream may harm your unborn baby. Breastfeeding women should not apply Wynzora® Cream directly to the nipple or areola; it is not known whether topically administered calcipotriene and betamethasone dipropionate is absorbed in human milk.

Please see Full Prescribing Information for Wynzora.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

References: 1. Pinter A, Iversen L, Praestegaard M, Stein Gold L. Fixed dose calcipotriene (CAL) and betamethasone dipropionate (BDP) cream significantly improves plaque psoriasis at week one in a pooled analysis of phase 3 data. Poster presented at: European Academy of Dermatology and Venereology Congress; September 7-10, 2022; Milan, Italy. 2. Stein Gold L, Green LJ, Dhawan S, Vestbjerg B, Praestegaard M, Selmer J. A phase 3, randomized trial demonstrating the improved efficacy and patient acceptability of fixed dose calcipotriene and betamethasone dipropionate cream. J Drugs Dermatol. 2021;20(4):420-425. doi:10.36849/JDD.2021.5653 3. Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol. 2011;25(suppl 4):9-14. doi:10.1111/j.1468-3083.2011.04060.x 4. Praestegaard M, Vestbjerg B, Selmer J, Holm-Larsen T. Phase 3 trial demonstrates superior patient treatment convenience of MC2-01 calcipotriene plus betamethasone dipropionate cream compared to current topical suspension. J of Skin. 2020;4(5):s62. 5. Wynzora® Cream. Package insert. MC2 Therapeutics; 2020.

pink close icon

Watch how PADTM Technology optimizes absorption of Cal and BDP3

Play button for Wynzora and PAD™ Technology mechanism of action video
Wynzora MOA video icon